[Articles] Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.
[Comment] Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
Obesity, overweight, and the consequences of excess adiposity continue to drive a substantial proportion of morbidity and mortality around the world. Prevention and treatment of obesity is an important strategy for preventing the development of multimorbidity.1 GLP-1 receptor monoagonists such as semaglutide2 or GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor multiagonists such as tirzepatide3 are […]
GLP-1 reduced migraine frequency by nearly half, in a pilot study – STAT
GLP-1 reduced migraine frequency by nearly half, in a pilot study STAT Diabetes drug may cut migraine days in half with little weight loss: Study ABC News – Breaking News, Latest News and Videos Diabetes drug cuts migraines in half by targeting brain pressure ScienceDaily Weight loss jab could be used to treat migraines The Independent From blood sugar […]
New weight-loss drug sails through all-important Phase III trial
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for US Food and Drug Administration approval. Continue Reading Category: Obesity, Illnesses and conditions, Body […]
Lilly expects orforglipron obesity results in third quarter – Reuters
Lilly expects orforglipron obesity results in third quarter Reuters Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly Lilly Obesity Pill to Rival Shots Holds Up to Scrutiny in Trial Bloomberg Eli Lilly’s phase 1 amylin […]
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Bernard Khoo, Tricia M-M Tan
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Agnes Gasiorek, Arne Heydorn, Sanaz Gabery, Julie B Hjerpsted, Katrine Kirkeby, Thomas Kruse, Signe B Petersen, Søren Toubro, Andreas Vegge, Cassandra Key
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Publication date: Available online 20 June 2025 Source: The Lancet Author(s): Kirsten Dahl, Søren Toubro, Sohan Dey, Ruben Duque do Vale, Anne Flint, Agnes Gasiorek, Arne Heydorn, Ania M Jastreboff, Cassandra Key, Signe Beck Petersen, Andreas Vegge, Kasper Adelborg
Novo is not dead yet! Novo Nordisk’s experimental drug results in up to 24% weight loss
June 20 (Reuters) – Novo Nordisk (NOVOb.CO) On Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a […]
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s – wired.com
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s wired.com Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine Eli Lilly Lilly expects orforglipron obesity results in third quarter Reuters Lilly Obesity Pill to Rival […]